Company ProfilePremium

Riken Vitamin Co., Ltd.

Company Profile Analysis

Ticker: 4526.T理研ビタミン株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Riken Vitamin Co., Ltd. - Company showcase

Year Founded & Workforce

1949

1,887 Employees

Riken Vitamin Co., Ltd. logo

Riken Vitamin Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Riken Vitamin Co., Ltd. Overview

ItemDetailSource
Legal name理研ビタミン株式会社 / RIKEN VITAMIN CO., LTD.YUHO-FY26 cover
Former namesRiken Vitamin Oil Co., Ltd. (理研ビタミン油株式会社), from 1949 to January 1980YUHO-FY26 history
Corporate lineageTraces to RIKEN (the Institute of Physical and Chemical Research, founded 1917) via predecessor Riken Eiyo Yakuhin (1938). The vitamin division personnel spun out in 1949.YUHO-FY26
Founding / incorporation27 August 1949, with capital of ¥3 millionYUHO-FY26; company IR deck Jan 2023
Incorporation jurisdictionJapan (Companies Act)YUHO-FY26
Corporate structureCompany with an Audit & Supervisory Committee (監査等委員会設置会社), adopted June 2017YUHO-FY26
Headquarters1-6-1 Yotsuya, Shinjuku-ku, Tokyo, Japan. Relocated from Chiyoda-ku in November 2020.YUHO-FY26
Exchange / tickerTokyo Stock Exchange Prime Market: 4526. Listed October 1961 (2nd Section), moved to 1st Section December 2014, Prime from April 2022.YUHO-FY26
ISIN / CUSIPconfirm via JPX. CUSIP not applicable (no US listing or ADR identified).—
Fiscal year end31 MarchTANSHIN-FY26
Share capital¥2,537 millionYUHO-FY26
Shares issued30,705,100 at 31 Mar 2026. Treasury shares were 1,517,289, including 187,988 held in BIP/ESOP trusts.TANSHIN-FY26
Employees (consolidated)1,887 at 31 Mar 2026, plus 453 average temporary staffYUHO-FY26
Employees (parent)1,016; average age 39.5; average tenure 15.5 years; average salary ¥8.41 millionYUHO-FY26
AuditorKPMG AZSA LLC (有限責任 あずさ監査法人), 20 consecutive years. Audit fee FY2026: ¥122 million.YUHO-FY26
Market capitalisation≈¥102.1 billion on issued-share basis at ¥3,325 (28 Sep 2026, kabuyoho). ≈¥95 billion excluding treasury shares (analyst estimate).kabuyoho; analyst calc
Group compositionParent plus 18 subsidiaries: 14 consolidated (4 domestic, 10 overseas) and 4 non-consolidatedYUHO-FY26
MetricFY2022FY2023FY2024FY2025FY2026
Employees consolidated (persons)1,8251,8481,8571,8581,887
Employees parent (persons)9589579669971,016
Temporary staff consolidated avg (persons)419430438451453

Source: YUHO-FY26, five-year summary.

Riken Vitamin is a mid-cap Japanese ingredients-and-foods maker whose identity comes from RIKEN's natural vitamin-A extraction work. Its core competence is extracting, purifying, concentrating and molecularly distilling natural raw materials, especially vegetable oils, seaweed, fish and plant pigments.

Consumers know it for "Fueru Wakame-chan" dried wakame, wakame soup and "Riken Non-Oil" dressings. Yet most sales and profit come from business-to-business products:

  • food-improving agents (emulsifiers such as distilled monoglycerides);

  • natural vitamin E antioxidants;

  • natural colours;

  • functional health ingredients;

  • seasonings and extracts;

  • polymer additives (anti-fog, anti-static, lubricant and plasticiser agents).

Overseas sales are about a quarter of the group, anchored by a core emulsifier plant in Malaysia. Management targets 35% overseas sales and ¥13.5 billion operating profit by the year ending March 2035.

The equity story combines three things: a cash-rich, low-leverage balance sheet; rising shareholder returns (a payout floor of 40% or more plus buybacks); and an ongoing unwinding of cross-shareholdings. It is constrained by low expected growth, which leaves the stock at about 1x P/B.


Company's own description

The annual report frames the group around the founding policy of "effective utilisation of natural resources" (天然物の有効利用). It describes a group that uses proprietary technology and development capability to create products in foods, food-improving agents, chemical-improving agents and vitamins, and supplies them in Japan and worldwide.

The stated management philosophy has five pillars:

  1. Contributing to healthy, rich diets through food.

  2. Compliance-based business conduct.

  3. A flexible, creative manufacturer that uses its own "production seeds" (raw materials, technologies and equipment).

  4. Building a "Riken Vitamin of the world" brand overseas.

  5. A respectful, attractive workplace.

Source: YUHO-FY26, section 1.

The long-term vision is "to become a company that grows by supporting a sustainable society with specialty products and services" (持続可能な社会をスペシャリティな製品とサービスで支え、成長する会社になる). The goal year was moved from the company's FY2030 to its FY2034 in May 2025. Source: MTP2027.

Reporting structure versus product structure

Riken Vitamin reports three geographically defined segments:

Domestic Food Business: household foods, commercial foods, and processed-food ingredients including food-improving agents and vitamins.

Domestic Chemical & Other Business: chemical-improving agents and feed additives or feed oils.

Overseas Business: food-improving agents, chemical-improving agents, extracts and seasonings.

Internally, and in investor presentations, management also describes the business by product field:

Foods: extracts and seasonings, seaweed.

Improving agents: emulsifiers, antioxidant-grade vitamins, colours.

Healthcare: nutritional-fortification vitamins, functional food ingredients, microcapsules.

Other: All vitamins are booked to Healthcare, because sales cannot be split by end use. Source: company IR deck, 9 Jan 2026.

Business model and revenue model

EngineCustomersEconomicsIndicative scale (FY2026)
Branded consumer foods (household)Supermarkets, drugstores and e-commerce, via wholesalersBrand-driven; high promotion and advertising intensity; volume-sensitive to price increases¥13,650 million (13.9% of gross segment sales)
B2B foods and food solutions (commercial plus processed-food ingredients)Processed-food manufacturers, convenience-store vendors, foodservice, school and industrial catering, bakeries, noodle makersSpecification-driven; application centres support co-development; price revisions lag input costs¥52,710 million (53.8%)
Industrial / chemical additives and overseas ingredientsPlastics converters, packaging-film makers, agricultural-film makers, rubber, cosmetics, feed; global food manufacturersCommodity-plus-specialty mix; exposed to palm and vegetable-oil pricing and to competition from Western and Chinese emulsifier makers¥31,579 million (Domestic Chemical plus Overseas, gross)

Riken Vitamin is a manufacturer whose revenue is almost entirely product sales recognised at a point in time. The annual report confirms that all FY2025 and FY2026 revenue is "goods transferred at a point in time", with no over-time revenue. There is no material subscription, licensing or service revenue.

Revenue is reduced by rebates and promotional allowances to distributors and retailers. These rebates are a critical accounting estimate: accrued promotion expenses were ¥636 million at FY2026 year-end. Source: YUHO-FY26 and TANSHIN-FY26 notes.

The model has three distinct economic engines:

Source: TANSHIN-FY26 segment breakdown; analyst grouping.

Value-chain position

Riken Vitamin sits mid-stream. It buys imported vegetable oils and palm derivatives, mainly through trading houses and oil refiners. It buys aquacultured wakame from Sanriku (Iwate and Miyagi), gardenia fruit and other botanicals, and animal-derived raw materials such as pork for extracts made in Oklahoma.

It converts these by distillation, esterification, extraction and blending into:

  • ingredients sold to food and chemical manufacturers; and

  • branded packaged foods sold through distribution.

It is also vertically integrated upstream in seaweed. Through subsidiary Riken Foods it runs wakame seedling development at "Yuriage Factory" in Natori, Miyagi (opened 2017), and land-based green-laver (スジアオノリ) aquaculture at "Rikuzentakata Base" in Iwate (opened October 2021). Source: YUHO-FY26 R&D section.

Independent characterisation

Riken Vitamin is best understood as a Japanese specialty lipid-chemistry and natural-extract company that happens to own a strong consumer brand franchise. The consumer image of "dressings and wakame" understates the B2B core, a point made explicitly by outside director Shinichi Hirano in the 2023 integrated report.

Key characteristics:

  • Profitability is moderate (operating margin 7–10% over FY2022–FY2026). It is constrained by domestic demographic decline, input-cost volatility and commoditisation of emulsifiers overseas.

  • The balance sheet is a defining feature: an equity ratio of about 72%, net cash, and ¥15 billion of investment securities.

  • The investment case therefore depends heavily on capital allocation (buybacks, cross-shareholding unwind, payout) as much as on operations.

  • The 2020 Qingdao accounting scandal is a governance legacy that shaped the current subsidiary-control framework and still colours investor perception.

Strategy

Stated strategy themes (MTP2027 and YUHO-FY26)

Riken Vitamin's long-term vision is to become a company that grows by supporting a sustainable society with specialty products and services. The goal year was reset in May 2025 to the year ending March 2035.

FY2035 quantitative goals (company "FY2034"):

  • Operating profit ¥13.5 billion.

  • Overseas sales ratio 35%, up from 25% in FY2025.

  • ROE of 10–12%.

MTP2027 (April 2025 – March 2028) is framed as three years of "aggressive capital investment and restructuring of the business framework in anticipation of demographic change". It combines:

  1. Strengthening domestic earnings sustainability:

    • Grow slightly faster than the processed-food market.

    • Invest in productivity and labour-saving automation at ageing plants.

    • Household: market-creating products and revitalising existing brands.

    • Commercial: ready-meal ("nakashoku/sokushoku") demand and labour-shortage-driven new markets.

    • Processed-food ingredients: substitutes for unstable raw materials, production-efficiency and food-loss solutions, and health markets.

    • Chemicals: concentrate on strength areas (lubricants, anti-fog agents, plasticisers, anti-static agents); expand biomass-based products; partner in non-core areas; support Japanese customers expanding abroad.

  2. Building a new overseas framework for a leap forward:

    • Front-load investment for specialty-product market expansion, concentrated on Rikevita Malaysia.

    • Break down domestic/overseas silos in production, sales, development and administration.

    • Restructure Chinese production lines and ramp the new Tianjin plant.

    • Build sales bases in each Southeast Asian country.

    • Use application centres for bakery.

    • Expand pork-extract capacity in the US.

  3. Shift to balance-sheet- and share-price-conscious management: an explicit TSE "cost of capital" response.

  4. Non-financial strategy: long-term R&D aimed at social issues; a new HR system based on the January 2025 "talent policy"; strengthened group governance.

MTP2027 targets and progress

KPIFY2025 actual (base)FY2026 actualFY2028 target (company "FY2027")
Net sales¥95.5bn¥96.3bn¥110.0bn
Operating profit (margin)¥8.7bn (9.1%)¥6.9bn (7.2%)¥10.0bn (9.1%)
EBITDA¥11.9bn¥11.5bn¥14.2bn
ROE12.1%8.7%≥10%
Payout ratio30.3%46.2%≥40%
Equity ratio70.1%71.6%60–65%
Cross-shareholdings / net assets19.0%17.9%<10%
SegmentSalesOperating profit
Domestic Food¥71.9bn¥7.5bn
Domestic Chemical¥9.7bn¥0.9bn
Overseas¥30.0bn¥1.6bn
Cash inCash out
Operating cash flow ¥28.0bnCapex ¥25.0bn, 2.5x the prior plan (domestic ¥13.0bn, overseas ¥12.0bn; by field: improvers ¥15.2bn, foods ¥7.1bn, healthcare ¥1.9bn, other ¥0.8bn)
Cross-shareholding sales ¥9.0bnShareholder returns of ¥12.4bn or more
Plus cash and debtStrategic investment (alliances, M&A, new businesses), with debt used if needed

FX assumption: ¥150/$. Sources: MTP2027; COC-2026.

Cash allocation over three years:

Target market value: "first, ¥100 billion market capitalisation and P/B consistently above 1x" (COC-2026). On an issued-share basis this was achieved around September 2026, at about ¥102 billion.

Progress assessment after year one:

  • Sales are tracking (FY2027 guidance is ¥100 billion).

  • Profitability is materially behind. Reaching ¥10 billion operating profit requires about +40% from the FY2027 guidance of ¥7.1 billion in one year, which looks unlikely without a sharp overseas recovery.

  • The FY2026 single-year plan (sales ¥100 billion, OP ¥8.5 billion, NP ¥8.2 billion, EBITDA ¥12.0 billion) was missed on every line (YUHO-FY26).

Initiatives in the last 24 months

InitiativeDateDetail
Southeast Asian sales subsidiariesJan–Apr 2025Vietnam and Thailand entities; consolidated from 31 Mar 2026
Talent policyJan 2025New HR philosophy: "respect individuality and raise each other; think and act autonomously". Talent portfolio of global, innovation, DX and management talent.
MTP2027 and vision resetMay 2025See above
Leadership transitionJun 2025Mochizuki becomes President
Soka renewable-energy upgradeApr 2025100 kW solar plus 200 kWh lithium-ion storage (Saitama Prefecture credit PR document)
Patto Jutto and Kakechae Ethnic launchesMar 2025; Feb 2026Category-creating household products
China rationalisationFY2026Commodity chemical lines in China stopped; staff shifted to the new food-improver plant
English simultaneous disclosure of full tanshinFrom FY2026 resultsIR enhancement (COC-2026)
Cost-of-capital frameworkJun 2025 and Jun 2026Cost of equity estimated at 8–9% (CAPM 6.6% plus investor hearings)
Guymon expansionDec 2023 – Aug 2027¥1.54 billion for +500 t pork-extract capacity
US subsidiary relocation to TexasAnnounced Jun 2026Expanded application centre and Ramen Lab
Anpachi (Gifu) new plantJun–Jul 2026¥3.6 billion land purchase; replaces the Kyoto colours plant; supports gardenia-blue demand after the 2025 FDA approval
Shareholder returns2025–2026Payout floor raised to 40%; ¥2 billion buyback in each of FY2026 and FY2027
Cross-shareholding unwindFY2026¥3.38 billion sold across 16 issues; Nomura, Riken Technos and Sumitomo Pharma fully exited; Itochu Shokuhin tendered in TOB

Management guidance

ItemH1Full year
Net sales¥49.5bn¥100.0bn (+3.8%)
Operating profit¥3.6bn¥7.1bn (+2.9%)
Ordinary profit¥3.8bn¥7.6bn (−1.4%)
Net profit¥2.9bn¥7.5bn (+6.6%)
EPS—¥256.96
DPS—¥110 (payout 42.8%)
ROE—9.0%
SegmentSalesOperating profit
Domestic Food¥67.2bn¥6.44bn
Domestic Chemical¥9.0bn¥0.86bn
Overseas¥25.8bn¥0.2bn loss

FY2027 guidance (13 May 2026, unchanged on 7 Aug 2026):

Segment guidance for the full year:

Source: SUPP-1Q27.

Products & Services

Sources: YUHO-FY26 business and R&D sections, TANSHIN-FY26 commentary, Integrated Report 2024, company IR decks (Jun 2025, Sep 2025, Jan 2026). Pricing is not disclosed for any product, so the pricing model column is omitted; consumer items are sold through retail at retailer-set prices. "Launch" is the original launch year where disclosed.

Domestic Food Business — Household Food

Product / brandDescription and capabilitiesTarget customerLaunch / latest
Fueru Wakame-chan® (ふえるわかめちゃん)Curled dried cut wakame that rehydrates and expands. The company claims No.1 share in domestic dried cut wakame. 50th-anniversary design renewal in 2026.Households1976; renewal 2026
Wakame Soup (わかめスープ)Instant wakame soup. The company claims No.1 share in instant wakame soup. 45th anniversary in 2026.Householdsc.1981; renewal 2026
Furikakeru Zakuzaku Wakame® (ふりかけるザクザクわかめ)Crunchy wakame topping. Volumes fell in FY2026, then grew in Q1 FY2027 after TV exposure and new SKUs.Households—
Tokimeki Kaisouya (ときめき海藻屋)Umbrella brand for seaweed products, signalling a shift from wakame to seaweed in general.Households2,016
Riken Non-Oil® (リケンのノンオイル) seriesOil-free dressings, the largest dressing franchise. Volumes declining after price revisions.Households1989 (Aojiso Super Dressing)
Selecty (セレクティ)Riken Non-Oil sub-brand. Volumes declined in Q1 FY2027.Households—
Yoshokuya-san no Tada Tada Oishii DressingWestern-style dressing; FY2026 contributor.Households—
Fuwajiso® Aojiso & Cheese DressingNew dressing; FY2026 contributor.HouseholdsFY2026
Kakechae Ethnic (かけちゃえエスニック)Non-oil dressing that turns food "ethnic" by pouring. 140,000 bottles shipped by end-April 2026; featured in Nikkei Trendy's H2 2026 break-out forecast.HouseholdsFeb 2026
Sozairyoku Dashi® (素材力だし)Salt-free Japanese dashi powder. FY2026 sales up on a Q3 TV campaign.Households2,000
Patto Jutto® (パッとジュッと)Pouch seasoning for freezer-marinating chicken breast. Technology limits drip loss when cooked from frozen. Cumulative FY2026 shipments exceeded 500,000 pouches.HouseholdsMar 2025

The company won the "Food Hit Award – Excellent Hit" three years running from 2022 (IR deck, Sep 2025). Specific winning SKUs are not itemised in the sources reviewed.

Domestic Food Business — Commercial Food

Product lineDescriptionTarget customerNotes
Seasonings and extracts for food makersRamen soups, snack seasonings, onigiri wakame and other custom seasoningsProcessed-food makers, convenience-store vendorsHeritage from 1963 "Riken Soup Stock"
Frozen seaweedFrozen wakame, mozuku and similar; new "Frozen Mozuku Kimchi" using Okinawa Katsuren mozukuFoodservice, cateringNew demand captured in FY2026
Egao de Lunch® (笑顔でランチ) seriesAllergen-considerate productsSchool lunches; expanding to industrial catering and family restaurantsBeing strengthened in FY2027
CVS seaweed productsSeaweed items for convenience-store supply chainsConvenience-store vendorsStrong in FY2026
Foodservice dressings and condimentsBulk formatsRestaurants, catering—

Domestic Food Business — Processed Food Ingredients (food-improving agents, vitamins, colours, healthcare)

Product lineDescription and specificationsTarget customerNotes
Emulsifiers (乳化剤), including distilled monoglyceridesImprove texture, shelf life and processing. Applications span bread, noodles, tofu, Japanese and Western confectionery, beverages, processed oils, frozen foods, delicatessen, meat products and cooked rice.Food manufacturersCore since 1960 (Osaka); developed at the Chiba A&I Center
Food-loss-reduction and quality-preservation solutionsFormulations extending shelf life and replacing unstable raw materials, e.g. egg-replacement during the "egg shock"Food manufacturersStrategic proposal theme
Natural vitamin E (天然ビタミンE)The company's "key material". Used as an antioxidant for food preservation and for nutritional fortification.Food and supplement makersOriginal vitamin heritage
Natural colours (天然系色素)Gardenia yellow, gardenia blue and other plant pigments. Gardenia blue received US FDA approval as a food colour in 2025 (per LOGI-TODAY), which the company expects to drive demand.Food and beverage makers, overseasMade at Kyoto (Kameoka); moving to Anpachi (Gifu) by c.FY2031
Crocetin (クロセチン)Gardenia-derived carotenoid functional ingredientHealth-food makersLaunched 2006
Mekabu fucoidanViscous polysaccharide from wakame sporophyllsHealth-food makersLaunched 2006
MicrocapsulesPharmaceutical and food encapsulation; solidifying flavours; stability and handling solutionsPharma and food makersR&D focus on functionality
Health-functional foods (健康機能食品)Functional ingredient formulations for supplements and foodsSupplement and food makersMade at Tokyo (Itabashi)

Domestic Chemical & Other Business

Product lineFunctionEnd marketsNotes
Anti-fog agents (防曇剤)Prevent condensation foggingFood wrap, agricultural greenhouse filmCore focus area under MTP2027
Anti-static agents (帯電防止剤)Suppress static and dust attractionPlastics, electronics packagingCore focus area
Lubricants (滑剤)Processing aids for polymersPlastics mouldingCore focus area
Plasticisers (可塑剤)Soften rigid resinsPVC, filmsCore focus area
Bio-based / biomass additivesPlant-derived polymer additivesEnvironmentally conscious plastics, cosmeticsGrowth theme in TCFD opportunity analysis
Cosmetics and toiletry additivesEmulsifiers and functional agentsCosmetics, toiletriesPart of solution business
Feed oils and feed additivesTraded or manufactured feed inputsLivestock feedSold via Eiken Shoji

Overseas Business

Product lineProducerSales territoriesNotes
Food-improving agents (emulsifiers)Rikevita Malaysia (core plant), Tianjin (new food-improver plant), parent exportsGlobal via 7 sales subsidiariesSpecialty versus commodity mix; commodity lines face price competition
Chemical-improving agentsRikevita Malaysia, Tianjin (commodity chemical lines in China ended FY2026), Shanghai chemical application centreChina, Southeast Asia, globalRationalisation under way
Pork and other extractsGuymon Extracts (Oklahoma)North America; Japan¥1.54 billion capacity expansion adding 500 t, completion August 2027
Ramen and bakery solutions (USA)RIKEN VITAMIN USA application centre and "Ramen Lab"North AmericaRelocating to Texas; expansion planned
SubsidiaryTerritory
Rikevita SingaporeSoutheast Asia, South Asia, Oceania
Rikevita Viet NamVietnam
Rikevita ThailandThailand
Riken Vitamin EuropeEurope, Africa, Middle East
Riken Vitamin USANorth and Latin America
Shanghai subsidiaryChina
Taiwan subsidiaryTaiwan, Korea

Sales-subsidiary territories (YUHO-FY26):

Financial Narrative

All figures are consolidated, Japanese GAAP, ¥ million unless noted.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsMain productsProducing entities

Domestic Food Business

Household foods; commercial foods; processed-food ingredients (raw materials, food-improving agents, vitamins)

Seaweed (wakame) products, dressings, extracts and seasonings, food-improving agents, vitamins, health-functional foods

Parent; Riken Foods (seaweed, extracts); Sunny Packaging (repacking); Eiken Shoji (distribution)

Domestic Chemical & Other Business

Chemical-improving agents; feed additives and feed oils

Lubricants, anti-fog agents, plasticisers, anti-static agents for plastics, films, rubber and cosmetics

Parent; Kenseido (chemical additives plant); Eiken Shoji (feed trading)

Overseas Business

Food- and chemical-improving agents, extracts, seasonings

Distilled monoglycerides and other emulsifiers, polymer additives, pork extracts

Rikevita Malaysia and Tianjin (manufacturing); Guymon Extracts (extracts); sales subsidiaries in Singapore, Vietnam, Thailand, Germany, USA, Shanghai and Taiwan

Revenue by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Domestic Food Business (JPY Mn)

54,13058,18663,15464,82166,360

Domestic Chemical & Other (JPY Mn)

6,6177,0317,7537,9598,686

Overseas Business, external (JPY Mn)

18,48323,53220,57622,80121,252

Consolidated net sales (JPY Mn)

79,23188,75091,48495,58296,300

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (FY2025–FY2026)

Sub-segmentFY2025FY2026

Household Food (JPY Mn)

13,58613,650

Commercial Food (JPY Mn)

22,75523,009

Processed Food Ingredients (JPY Mn)

28,48029,701

Results by Segment and Segment Margins & Growth (%)

MetricFY2025FY2026

Domestic Food segment profit (JPY Mn)

6,6596,417

Domestic Chemical segment profit (JPY Mn)

895857

Overseas segment profit (JPY Mn)

1,120-436

Adjustments (JPY Mn)

4962

Consolidated operating profit (JPY Mn)

8,7246,900

Domestic Food margin (%)

10.39.7

Domestic Chemical margin (%)

11.29.9

Overseas margin on gross sales (%)

4.6-1.9

Revenue by Segment (%)

SegmentFY2025FY2026

Domestic Food share (%)

66.867.7

Domestic Chemical share (%)

8.28.9

Overseas share (%)

25.023.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Overview — Domestic Food

SegmentQ1Q2Q3Q4

Domestic Food (JPY Mn)

2,0401,4911,5501,335

Domestic Chemical (JPY Mn)

270200204181

Overseas (JPY Mn)

082-179-338

Consolidated (JPY Mn)

2,3651,7261,6241,184

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Net sales (JPY Mn)

79,23188,75091,48495,58296,300

Gross profit (JPY Mn)

25,56427,24429,88631,27029,767

SG&A (JPY Mn)

19,72320,08520,51422,54522,866

Operating profit (JPY Mn)

5,8407,1589,3718,7246,900

Depreciation, derived (JPY Mn)

3,7363,7183,3303,2044,677

EBITDA (JPY Mn)

9,57610,87612,70111,92811,577

Ordinary profit (JPY Mn)

6,1827,72310,2969,4177,704

Extraordinary income (JPY Mn)

14,3431942,3644,5032,835

Extraordinary losses (JPY Mn)

213607511,214295

Pre-tax income (JPY Mn)

20,3137,85711,90912,70610,244

Net income attributable to owners (JPY Mn)

21,5826,4148,7559,3887,035

EPS basic (JPY)

657.98195.51268.44310.08238.19

EPS diluted (JPY)

657.98195.51268.44310.08238.19

Dividend per share (JPY)

46598194110

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

32.330.732.732.730.9

Operating margin (%)

7.48.110.29.17.2

EBITDA margin (%)

12.112.313.912.512.0

Net margin (%)

27.27.29.69.87.3

Net sales growth YoY (%)

1.912.03.14.50.8

Operating profit growth YoY (%)

327.222.630.9-6.9-20.9

Balance Sheet and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (JPY Mn)

102,660105,223118,776112,999116,387

Cash and cash equivalents (JPY Mn)

15,06416,65620,14118,83519,131

Interest-bearing liabilities, company definition (JPY Mn)

18,64715,69317,22311,0338,396

Net debt, negative = net cash (JPY Mn)

3,583-963-2,918-7,802-10,735

Net assets (JPY Mn)

66,53971,37176,64379,20083,379

Equity ratio (%)

64.867.864.570.171.6

BPS (JPY)

2,027.842,174.392,523.842,649.952,855.29

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2025FY2026

Short-term borrowings incl. current portion of LT debt (JPY Mn)

3,3731,941

Long-term borrowings (JPY Mn)

6,5415,200

Goodwill and intangibles (JPY Mn)

9801,011

Investment securities (JPY Mn)

15,07815,025

Current assets (JPY Mn)

65,69966,227

Current liabilities (JPY Mn)

21,12919,434

Working capital (JPY Mn)

44,57046,793

Inventories (JPY Mn)

19,61022,061

Asset retirement obligations (JPY Mn)

6102,204

Retirement benefit asset (JPY Mn)

4,1044,784

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (JPY Mn)

6,8237,83510,4517,8925,963

Investing cash flow (JPY Mn)

-3,661-2,034-5543531,747

Financing cash flow (JPY Mn)

-7,565-4,578-7,084-9,965-8,040

Capex, PP&E purchases (JPY Mn)

3,2502,1122,5364,6784,863

FCF, OCF minus capex (JPY Mn)

3,5735,7237,9153,2141,100

FCF, company definition OCF+ICF (JPY Mn)

3,1625,8019,8978,2457,711

Dividends & Capital Returns

ItemFY2024FY2025FY2026

Dividends paid (JPY Mn)

—2,7763,242

Treasury share purchases (JPY Mn)

≈6,360 (Kikkoman block, Feb 2024; MTP2027 cites ¥6.3 billion)

1,1332,000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

38.39.311.812.18.7

ROA, net income / total assets (%)

21.06.17.48.36.0

Interest coverage, OCF / interest paid (x)

24.961.392.269.251.7

Payout ratio, consolidated (%)

7.030.230.230.346.2

PER at fiscal year-end (x)

2.59.89.67.812.1

Returns & Leverage Ratios (%) and Financial Ratios (x) (FY2025–FY2026)

RatioFY2025FY2026

ROIC, NOPAT at 30% tax / (equity + debt − cash) (%)

8.66.7

Current ratio (x)

3.113.41

Debt / equity, company-defined debt (x)

0.140.10

Net debt / EBITDA (x)

-0.65-0.93

Operating profit / interest expense (x)

70.960.5

Asset turnover, sales / average total assets (x)

0.820.84

DSO (days)

8386

DIO, on cost of sales (days)

111121

DPO, on cost of sales (days)

4543

Cash conversion cycle (days)

150164

Revenue by Region and Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024FY2025

Japan (JPY Mn)

61,36761,00265,22070,90872,786

Other / overseas (JPY Mn)

16,35418,22823,53020,57522,796

Overseas share of sales (%)

21.023.026.522.523.8

Region Margins & Growth (%)

RegionFY2022FY2023FY2024FY2025

Japan growth (%)

-0.66.98.72.6

Other / overseas growth (%)

11.529.1-12.610.8

Geographic Revenue

RegionFY2026 performanceQ1 FY2027 performance (SUPP-1Q27)

North America

Sales up; major-customer adoption from Q2; extract growth. The fastest-growing region.

Sales up; improver sales to major customers expanding; extracts strong; US tariff refund recognised

Taiwan

Sales up; the only region with volume growth

Sales up

China

Volume decline continued on sluggish consumption

Food-improver volumes above prior year as recovery measures take effect

Southeast Asia

Volume decline; intensified price competition in general-purpose products

Sales up (FX and volume)

Europe

Volume decline; price competition

Sales up (FX and volume)

Share Price

MetricFY2022FY2023FY2024FY2025FY2026

Share price high (JPY)

1,9782,0892,6262,8793,285

Share price low (JPY)

1,3371,5741,9002,3002,204

Riken Vitamin TSR index

126.2148.6202.5197.7239.0

TOPIX incl. dividends index

102.0107.9152.5150.2202.2

Valuation Multiples

MultipleRiken VitaminPrime-food median (COC-2026, Mar 2026)

P/E trailing (FY2026 EPS ¥238.19)

14.0x

about 14x

P/E forward (FY2027 guidance EPS ¥256.96)

12.9x—

P/B (FY2026 BPS ¥2,855.29)

1.16x (kabuyoho 1.14x on Q1 BPS)

about 1.3x

EV/EBITDA (FY2026)

≈7.2x

—

EV/Sales (FY2026)

≈0.87x

—

Dividend yield (FY2027 DPS ¥110)

3.31%—

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Annual DPS (JPY)

46598194110

Interim DPS (JPY)

212330.540.555

Consolidated payout ratio (%)

7.030.230.230.346.2

Capital Programmes

ProgrammeSharesAmountStatus

2016 self-TOB

6.6 million (pre-split)

≈¥24.4 billion

Completed

Feb 2024 ToSTNeT-3 (Kikkoman)

2,473,900

¥6.36 billion

Completed

Feb 2025 ToSTNeT-3

487,100

¥1.13 billion

Completed

May 2025 – Mar 2026 market purchases

696,500

¥2.00 billion

Completed

Jun – Sep 2026 market purchases (cap 900,000 / ¥2.0 billion)

522,600 at 31 Aug

¥1.63 billion at 31 Aug

Expired 30 Sep 2026; final result pending disclosure

Cancellations

7,000,000 (May 2022); 3,000,000 (Mar 2025)

——

Bucket Details

BucketJPY Mn

Within 1 year (short-term ¥600 plus current long-term ¥1,341)

1,941

1–2 years

5,141

2–3 years

59

Beyond 3 years

0

Total borrowings

7,141

Analyst Conclusions

Guidance and expectations

Company guidance for FY2027 (unchanged at Q1): sales ¥100.0 billion (+3.8%), OP ¥7.1 billion (+2.9%), NP ¥7.5 billion (+6.6%), DPS ¥110, ROE 9.0%. Guidance embeds:

  • an Overseas full-year loss of ¥200 million, despite a Q1 profit of ¥151 million;

  • continuing asbestos charges (Q1: ¥187 million);

  • labour-cost inflation (+¥470 million in Q1);

  • FX of about ¥150/$, versus a Q1 average of ¥160/$.

Q1 progress: OP ¥2.25 billion is 31.7% of the full-year plan and ordinary profit is 33.5%. The company typically front-loads profit in Q1 (FY2026 Q1 was 34% of full-year OP), so the progress rate alone does not signal a beat.

Consensus expects ordinary profit of about ¥8.7 billion, implying the market sees the guidance as conservative. Investors cite "conservative guidance" as one reason for the discount (COC-2026).

Bull case

  1. Overseas inflection is real. Q1 FY2027 overseas sales rose 18.3%, with a return to profit in all regions on volume recovery, North American adoption and China food-improver recovery. Guymon capacity (+500 t, Aug 2027) and US natural-colour demand add structural growth. A move from −¥436 million toward the ¥1.6 billion FY2028 target could add more than ¥2 billion to operating profit.

  2. Capital efficiency has a long runway. Equity ratio 71.6% versus a 60–65% target; cross-holdings of ¥15.0 billion (17.9% of net assets) versus a target below 10%; net cash. The 40%+ payout plus recurring ¥2 billion buybacks (about 2% of market cap a year) supports a total yield above 5% and steady EPS accretion. EPS rose 2.5x in ten years while the share price rose only 1.4x (COC-2026).

  3. Normalised margin recovery. The FY2026 operating margin of 7.2% included about 90 bp of one-off asbestos charges. As depreciation steps plateau and price revisions catch up, a return toward the 9–10% achieved in FY2024–FY2025 would imply ¥9–10 billion of OP on ¥100 billion of sales. Applying a 14x sector-median P/E to the resulting EPS would justify a materially higher price.

Bear case

  1. Structural margin squeeze. Wage inflation (5.5% parent base-up), depreciation up 46%, and recurring asbestos charges against a stagnant domestic volume base suggest the FY2024 margin peak was cyclical. The MTP2027 target of ¥10 billion OP is already out of reach on guidance (¥7.1 billion).

  2. Earnings quality and cash conversion. About a third of pre-tax profit comes from selling cross-shareholdings, a finite source. OCF-minus-capex FCF was only ¥1.1 billion in FY2026, and ¥25 billion of capex (including the ¥3.6 billion Anpachi land before construction cost) will keep FCF thin through FY2028, potentially forcing reliance on balance-sheet cash to fund returns.

  3. Overseas commoditisation and geopolitics. General-purpose emulsifiers face price competition in Europe and Southeast Asia. China remains fragile. US tariff policy is unpredictable: Q1's tariff refund flatters results, while Malaysia-to-US flows remain exposed. The FY2027 guidance itself assumes an overseas loss.

Catalysts and monitorables (next 12 months)

TimingItemWhat to watch
Early Oct 2026Final buyback tally (Jun–Sep programme)Completion versus ¥2.0 billion cap
Mid-Nov 2026H1 FY2027 resultsOverseas profitability persistence; asbestos run-rate; any guidance revision versus consensus ¥8.7 billion ordinary profit
Late Oct / Nov 2026Interim dividend¥55 confirmed
Feb 2027Q3 FY2027North America and China trends; Q3 has historically disappointed (Feb 2026 shares fell 6.6% on results)
May 2027FY2027 results, FY2028 guidance, new buybackWhether management reaffirms or resets MTP2027 targets; payout and buyback for the plan's final year
Aug 2027Guymon expansion completionUtilisation ramp
Autumn 2027Anpachi land title transfer; plant capex disclosureTotal project cost and return on investment
OngoingCross-shareholding salesProgress from 17.9% toward below 10% of net assets
OngoingUS tariffs, palm and vegetable-oil prices, JPY/USDEarnings sensitivity
OngoingRiken Non-Oil volume trend; 50th-anniversary wakame campaignHousehold franchise health

Analyst verdict

Riken Vitamin is a well-capitalised, technology-rich but under-earning mid-cap. It has spent the five years since the 2020 Qingdao scandal rebuilding credibility, and has largely succeeded in governance and capital-markets terms:

  • the Kikkoman overhang is gone;

  • cross-holdings are falling;

  • payout has risen from 30% to over 40%;

  • buybacks are now annual;

  • the stock has crossed the company's own "first milestone" of a ¥100 billion market capitalisation.

Five-year TSR has beaten TOPIX.

The operating story has gone backwards since FY2024. Operating profit fell 26% over two years. The first year of MTP2027 missed every financial target. Overseas, meant to be the growth engine toward a 35% sales share, swung to a loss. Meanwhile depreciation, wages and legacy asbestos liabilities are rising, and the ¥25 billion capex programme has yet to show returns. Reported net profit has been propped up by one-off securities gains, and true free cash flow has thinned sharply.

The Q1 FY2027 overseas turnaround is the most important recent data point. It should not be over-read: management still guides to an overseas loss for the year, and part of the improvement was a tariff refund.

On balance, the shares at about 12.9x forward earnings, about 1.15x book and a 3.3% yield are fairly valued for a low-growth, high-return-of-capital profile. They offer asymmetric upside only if overseas profitability proves durable. Key confirmation points are H1 FY2027 (November 2026) and the FY2028 guidance in May 2027.

Downside appears cushioned by net cash, about ¥15 billion of saleable securities, and a committed payout floor. The more likely path is a gradual re-rating toward sector multiples as capital is returned, rather than a growth-led re-rating. MTP2027's ¥10 billion operating-profit goal should be treated as aspirational. Investors should anchor on about ¥7–8.5 billion of operating profit for FY2027, the range between company guidance and implied consensus.

Stance: Neutral, with a positive bias contingent on overseas delivery.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitle / responsibilitiesBornBackgroundShares held (000)

Kazuhiko Yamaki (山木一彦)

Chairman of the Board

Feb 1959

Joined 1983; commercial-foods sales chief; Director 2010; President June 2016 – June 2025 (steered the post-scandal recovery)

16

Tsutomu Mochizuki (望月敦)

Representative Director & President (from June 2025)

Mar 1962

Joined 1985 (Tokyo University of Fisheries graduate); President of Riken Vitamin Europe GmbH (2004); head of International Business; 2nd Production Division; Executive Officer 2014; Director 2022; Managing Director 2023

7

Nobuo Dotsu (道津信夫)

Representative Director, Senior Managing; administration (compliance, GA, HR), business strategy

Aug 1960

Joined 1985; head of food-improver development; Executive Officer 2014

6

Takahiro Tomitori (冨取隆浩)

Managing Director; sustainability, accounting, systems, corporate strategy; GM Corporate Planning (from April 2026)

Aug 1965

Ex-Dai-Ichi Kangyo / Mizuho Bank (Executive Officer, Fukuoka branch GM); Mizuho Research Institute; joined 2021

2

Masaaki Nakano (中野正明)

Director; food-improver business, international business, chemical business

Jan 1965

Joined 1987; processed-food sales; global marketing; Executive Officer 2020

5

Takumi Aoki (青木巧)

Director (new, June 2026); food business, healthcare business

Mar 1966

Joined 1988; branch manager; commercial-foods sales chief; Executive Officer 2019

3

Shinichi Hirano (平野伸一)

Independent Outside Director

Jan 1956

Former President of Asahi Breweries (2016); outside director at Gig Works and Shinko Kogyo

2

Takehiko Makinodan (牧之段武彦)

Director, Full-time Audit & Supervisory Committee Member

Oct 1962

Joined 1986; Chiba plant manager; head of production; head of quality assurance

10

Satoshi Fujinaga (藤永敏)

Independent Outside Director, Full-time A&SC Member; chairs Nomination and Remuneration Committees

Sep 1959

Ex-Takeda Pharmaceutical (Asia-Pacific VP); pharmacist; outside auditor from 2015

5

Nagahisa Sueyoshi (末吉永久; registered name 權正永久)

Independent Outside Director, A&SC Member

Apr 1968

Attorney (Mukai Law Office); former civil conciliation officer

4

Wataru Sueyoshi (末吉亙)

Independent Outside Director, A&SC Member

Oct 1956

Attorney (KTS Law Office; ex-Mori Hamada & Matsumoto); outside director at Mitsubishi Estate

0

Ayumi Ujihara (氏原亜由美)

Independent Outside Director, A&SC Member

Sep 1961

CPA; ex-PwC Aarata partner; outside auditor at Yamaha Motor; outside director at Makita

0

Directors' Remuneration

CategoryHeadcountTotal (JPY Mn)FixedBonusPerformance share (non-cash)

Directors excluding A&SC members and outside directors

62231654710

A&SC member directors (internal)

21717——

Outside directors

56060——

Board & Management Changes

DateChangeContext

Jun 2016

Yamaki appointed President

Succeeded Miho Sakai

Nov 2020

Management-responsibility measures after Qingdao scandal

TDnet 19 Nov 2020

Jun 2021

Tomitori (ex-Mizuho) and Hirano (ex-Asahi) join the board

Post-scandal governance reinforcement

Jun 2023

Ujihara (CPA) joins as A&SC member; second woman on board

—

Jun 2025

Mochizuki becomes President; Yamaki becomes Chairman

Announced 30 Apr 2025, to run MTP2027 with new leadership. Mochizuki's international background aligns with the overseas-growth emphasis.

Jun 2026

Takahisa Nakano (Rep. Senior Managing) retires from board; Aoki joins

AGM 23 Jun 2026

Major Shareholders

RankHolderShares (000)%
1

Riken Vitamin Business Partners' Shareholding Association

3,35111.40
2

Master Trust Bank of Japan (trust account)

1,8036.13
3

Master Trust Bank of Japan (retirement benefit trust, Miyoshi Oil & Fat)

1,0803.67
4

Riken Vitamin Employee Shareholding Association

7722.62
5

Sumitomo Life Insurance

7262.47
6

Mizuho Bank (via retirement benefit trust)

6932.36
7

Asahi Mutual Life Insurance

4381.49
8

Custody Bank of Japan (trust account)

4251.44
9

Shimizu Foods (清水食品)

3551.21
10

Mitsubishi UFJ Trust & Banking

3361.14
—

Top 10 total

9,982

33.98

Major Shareholders by Holder Type

Holder type%

Individuals and others

46.01

Financial institutions

21.63

Other corporations

19.50

Foreign

11.52

Securities firms

1.33

Competitive Landscape

Competitors by Segment

Segment / categoryKey competitorsNotes on relative positioning

Household dressings

Kewpie (2809); Mizkan (private); Nisshin OilliO (2602); Ajinomoto (2802)

Kewpie is the dominant mayonnaise and dressing player: FY11/2025 sales ¥513.4 billion, OP ¥34.6 billion (Kewpie tanshin, 14 Jan 2026). Riken is the oil-free specialist.

Dried wakame and wakame soup

Various seaweed processors and private brands; instant-soup makers (e.g. Nagatanien, Ajinomoto)

Riken claims No.1 share in domestic dried cut wakame and instant wakame soup (IR deck Jan 2026); share percentage not disclosed

Dashi / seasonings

Ajinomoto (Hondashi); Yamaki (private); Shimaya (private); Kikkoman

Riken is niche (salt-free "Sozairyoku"); share not disclosed

Food emulsifiers (Japan)

Taiyo Kagaku (2902); Mitsubishi Chemical (sugar esters); Sakamoto Yakuhin Kogyo (polyglycerol esters); Kao

Taiyo Kagaku FY3/2026: sales ¥52.5 billion, OP ¥7.1 billion (13.5% margin) (Taiyo Kagaku tanshin, 11 May 2026)

Food emulsifiers (global)

IFF (ex-DuPont/Danisco), Palsgaard (private, Denmark), Kerry, Corbion, BASF, Chinese producers

Riken is a mid-sized Asian-based distilled-monoglyceride producer, exposed to commodity price competition per FY2026 commentary.

Natural colours

San-Ei Gen F.F.I. (private), Oterra (private), Givaudan Sense Colour, Sensient

Riken is strong in gardenia colours; gardenia blue is an opportunity after the FDA decision

Natural vitamin E

DSM-Firmenich, BASF, Eisai Food & Chemical, ADM, Chinese producers

Riken positions natural vitamin E as a "key material"

Polymer additives

ADEKA (4401), Kao, Sakamoto Yakuhin, Riken Technos (compounder, not a direct rival), global additive majors

Riken holds ADEKA shares (¥1.17 billion), a cross-holding with a business partner and competitor

Pork extracts (US)

US flavour and extract houses (e.g.

Guymon is a niche producer

Peer Comparison FY2011

MetricRiken Vitamin (FY3/2026)Taiyo Kagaku (FY3/2026)Kewpie (FY11/2025)

Net sales

¥96.3bn

¥52.5bn

¥513.4bn

Sales growth

+0.8%+4.9%+6.1%

Operating profit

¥6.9bn

¥7.1bn

¥34.6bn

Operating margin

7.2%13.5%6.7%

ROE

8.7%9.9%9.7%

Equity ratio

71.6%79.4%67.4%

R&D intensity

4.1%——

Recent Developments

--

Company Snapshot

$643.3M

Revenue

1,887

Employees

1949

Founded

Tokyo, Japan

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet. Equity ratio 71.6% and net cash of about ¥10.7 billion (company-defined debt ¥8.4 billion versus cash ¥19.1 billion). There is an unused ¥6.0 billion commitment line and ¥15.0 billion of investment securities (TANSHIN-FY26; YUHO-FY26).
  • Category-leading consumer brands. The company claims No.1 share in dried cut wakame and instant wakame soup. Fueru Wakame-chan has a 50-year franchise (IR deck Jan 2026; YUHO-FY26).
  • Technology depth and R&D intensity. R&D is ¥3.99 billion, 4.1% of sales, above typical Japanese food peers, backed by four application centres (YUHO-FY26).
  • Diversified, B2B-heavy mix. Processed Food Ingredients (¥29.7 billion) is the largest sub-segment and grew 4.3% in FY2026, cushioning the household weakness (TANSHIN-FY26).
  • Shareholder-return commitment. Payout floor of 40% or more; DPS raised from ¥46 to ¥110 in four years; ¥2.0 billion buybacks in consecutive years. TSR over five years was 239.0 versus 202.2 for TOPIX with dividends (YUHO-FY26).
  • Upstream supply security in seaweed. Proprietary seedling selection and aquaculture partnerships (Yuriage, Rikuzentakata, Ofunato) help protect wakame supply against climate-driven yield volatility (YUHO-FY26).

Weaknesses

  • Profit erosion. Operating profit fell 26% from the FY2024 peak (¥9.37 billion to ¥6.90 billion); margin fell from 10.2% to 7.2% (SUPP-1Q27).
  • Overseas unprofitability. Overseas segment lost ¥436 million in FY2026, and FY2027 guidance is still a ¥200 million loss despite a ¥30 billion / ¥1.6 billion FY2028 target (TANSHIN-FY26; SUPP-1Q27).
  • Earnings quality. Net profit relies on ¥2.6–4.1 billion of annual securities-sale gains, about 37% of FY2026 pre-tax income (TANSHIN-FY26).
  • Weak cash conversion. OCF fell 24% to ¥5.96 billion; OCF-minus-capex FCF was only ¥1.1 billion; the cash conversion cycle is about 164 days (analyst calc).
  • Ageing asset base and legacy liabilities. Asbestos ARO raised by ¥1.53 billion; asset retirement obligations quadrupled from ¥610 million to ¥2.20 billion (TANSHIN-FY26).
  • Governance legacy. The 2020 Qingdao fraud led to restatements, a material weakness, TSE supervision designation and a qualified auditor review conclusion (TDnet 2020–2021). Board independence of 42% and female representation of 17% are modest.

Opportunities

  • Natural-colour demand in the US. The 2025 FDA approval of gardenia blue, together with the Anpachi plant, positions Riken for the US synthetic-to-natural transition (LOGI-TODAY, 23 Jul 2026).
  • North America expansion. Major-customer emulsifier adoption since Q2 FY2026; Guymon +500 t capacity by August 2027; Texas relocation with a larger application centre and Ramen Lab (YUHO-FY26; SUPP-1Q27).
  • Labour-shortage and food-loss solutions in Japan. MTP2027 targets +¥3.6 billion of sales in Processed Food Ingredients and +¥2.3 billion in Commercial Food by FY2028.
  • Balance-sheet optimisation. Moving the equity ratio from 71.6% to the 60–65% target implies roughly ¥8–13 billion of capacity for returns or M&A at current asset levels (analyst calc).
  • Bio-based chemical additives. The TCFD analysis lists plant-derived additives for environmentally friendly plastics and cosmetics as an opportunity (YUHO-FY26).
  • Blue carbon and aquaculture. Seaweed CO₂-fixation research and land-based aquaculture could create new revenue (MTP2027; YUHO-FY26).

Threats

  • US trade policy. Malaysia-to-US improver exports are directly exposed. A tariff refund helped Q1 FY2027, highlighting volatility (MTP2027; SUPP-1Q27).
  • Chinese demand weakness. Persistent volume declines in China through FY2026 (TANSHIN-FY26).
  • Raw-material and energy inflation. Middle East tensions cited as driving raw-material and energy prices in the FY2027 outlook (TANSHIN-FY26); Domestic Chemical margin already squeezed.
  • Commoditisation and price competition. Explicitly cited in Europe and Southeast Asia general-purpose products (TANSHIN-FY26).
  • Climate change affecting wakame and vegetable oils. The TCFD scenario analysis flags raw-material production decline and procurement-cost increases as large financial-impact items (YUHO-FY26).
  • Domestic demographic decline. Listed as the first principal risk; shrinking market and intensifying competition (YUHO-FY26).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Vietnam and Thailand subsidiaries begin operations; Soka solar plus battery installedSoutheast Asian go-to-market; decarbonisation
30 Apr 2025Board decides President change (Mochizuki); ¥2.0 billion / 1.0 million-share buyback authorised (26 May 2025 – 24 Mar 2026)New leadership for MTP2027; capital return
14 May 2025FY2025 results: record sales ¥95.6 billion; OP −6.9% to ¥8.7 billion; ROE 12.1%. MTP2027 announced.Previous plan targets met; new growth and capex agenda
22 May 2025Year-end dividend ¥53.50 (annual ¥94)Payout 30.3%
24 Jun 202589th AGM: 12 directors elected; Mochizuki President, Yamaki ChairmanGovernance transition
8 Aug 2025Q1 FY2026: sales −1.6% (¥23.3 billion), OP −6.2%, NP −23%. Overseas weakness; FX loss ¥147 million.Early warning on overseas
27 Oct 2025Interim dividend ¥55Step-up toward 40% payout
13 Nov 2025H1 FY2026: sales +0.2% (¥47.3 billion); OP −11.6% (¥4.1 billion); NP +3.3%Profit erosion visible
9 Jan 2026Individual-investor briefing by President MochizukiRetail-holder expansion (+11,000 in FY2026)
Feb 2026"Kakechae Ethnic" non-oil dressing launchedHousehold innovation
12 Feb 2026Q3 FY2026 results (cumulative OP ¥5.7 billion; Overseas Q3 loss). Shares fall 6.6% on 13 Feb, from ¥3,275 to ¥3,060 (kabutore).Market reaction to overseas deterioration
12 Feb 2026Stock hits then-record ¥3,285 intraday (Matsui)Re-rating on capital policy
Mar 2026Certified "Health & Productivity Outstanding Organisation – White 500" for the 3rd consecutive yearHR and ESG credential
24 Mar 2026Buyback programme completed: 696,500 shares for ¥2.0 billionReturn delivered
31 Mar 2026Vietnam and Thailand consolidatedScope change
13 May 2026FY2026 results: sales ¥96.3 billion (+0.8%); OP ¥6.9 billion (−20.9%); NP ¥7.0 billion (−25.1%). ¥872 million asbestos ARO estimate change. FY2027 guidance OP ¥7.1 billion. New ¥2.0 billion / 900,000-share buyback (1 Jun – 30 Sep 2026).Large miss versus MTP year-one plan; shares hit 2026 low of ¥2,662 the same day (Matsui)
20 May 2026Year-end dividend ¥55 (annual ¥110; payout 46.2%)Dividend maintained despite profit fall
19 Jun 2026Annual securities report filed. Discloses plan to move US subsidiary to Texas and expand application centre and Ramen Lab; Guymon expansion schedule; cross-shareholdings at 17.9% of net assets.Strategic detail
23 Jun 202690th AGM; Takumi Aoki joins board; cost-of-capital update published (cost of equity 8–9%; PER is "the issue")Capital-markets narrative
Jun 2026Sale contract signed for Anpachi, Gifu plant landDomestic production reorganisation
21 Jul 2026Anpachi land acquisition announced: ¥3.6 billion, 48,000 m²; new plant replacing Kyoto; start-up targeted FY2031Capacity for colours and crocetin; gardenia-blue export opportunity
Jul 2026Itochu Shokuhin shares tendered in TOB (fully sold by 19 Jun filing date)Cross-holding reduction
7 Aug 2026Q1 FY2027: sales +8.1% (¥25.1 billion), all segments up; OP −4.9% (¥2.25 billion); Overseas back to profit (¥151 million) on volume recovery, North America, US tariff refund; asbestos impact ¥187 million; FX ¥160/$ versus ¥143Overseas inflection; guidance maintained
1 Sep 2026Buyback progress: cumulative 522,600 shares, ¥1.63 billion at 31 Aug 2026Programme about 81% complete by value
Sep 2026Shares trade ¥3,280–¥3,365, above the February record; market cap about ¥102 billion on issued shares (kabuyoho)"¥100 billion market cap" milestone in COC-2026 reached
25 Sep 2026Analyst consensus ordinary profit for FY2027 at ¥8.7 billion versus company ¥7.6 billion (kabuyoho)Street expects beat
30 Sep 2026Buyback authorisation expires; final tally not yet located at research dateMonitor TDnet early-October disclosure
2026 (ongoing)50th anniversary of Fueru Wakame-chan; 45th of Wakame Soup; packaging renewalsBrand reactivation

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Net sales rose from JPY 79,231 Mn in FY2022 to JPY 96,300 Mn in FY2026.
Riken Vitamin Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (JPY Mn)FY2022FY2023FY2024FY2025FY2026
Net sales79,23188,75091,48495,58296,300
Gross profit25,56427,24429,88631,27029,767

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Riken Vitamin, Consolidated Financial Results FY ended 31 Mar 2026 (English), 13 May 2026 (rikenvitamin.jp)
  2. Riken Vitamin, Annual Securities Report, 90th term, 19 Jun 2026 (EDINET S100YFDJ) (disclosure2dl.edinet-fsa.go.jp)
  3. Riken Vitamin, Q1 FY2027 Supplementary Materials, 7 Aug 2026 (www2.jpx.co.jp)
  4. Riken Vitamin, Medium-Term Management Plan 2027, 14 May 2025 (www2.jpx.co.jp)
  5. Riken Vitamin, Cost of capital and share price update, 23 Jun 2026 (rikenvitamin.jp)
  6. Riken Vitamin, Buyback status, 1 Sep 2026 (www2.jpx.co.jp)
  7. Riken Vitamin, Kikkoman alliance dissolution and ToSTNeT-3 buyback, Feb 2024: and: www2.jpx.co.jp · www2.jpx.co.jp
  8. Riken Vitamin, 2016 self-tender result (www2.jpx.co.jp)
  9. Riken Vitamin, Qingdao Fusheng disclosures (2020–2021) · www2.jpx.co.jp · www2.jpx.co.jp · www2.jpx.co.jp
  10. Reuters via SBBIT, Qingdao sale (8 Jun 2021) and TSE supervision release (28 Oct 2020) · sbbit.jp
  11. LOGI-TODAY, Anpachi plant land (23 Jul 2026) (logi-today.com)
  12. Riken Vitamin IR decks (Jan 2026; Sep 2025; Jun 2025) and Integrated Report 2024/2025 (rikenvitamin.jp)
  13. kabuyoho (price, consensus, valuation, Sep 2026) (kabuyoho.jp)
  14. Matsui Securities (price data) (finance.matsui.co.jp)
  15. the-shashi.com (segment and geographic history) (the-shashi.com)
  16. finboard (ownership history; capex history) · finboard.net
  17. envalith (five-year financial summary) (envalith.com)
  18. EDINET DB (corporate history) (edinetdb.jp)
  19. Taiyo Kagaku FY3/2026 results (assets.finboard.net)
  20. Kewpie FY11/2025 results (kewpie.com)
  21. kabutore (2016 TOB price; 2020 split; daily prices) (kabutore.biz)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.